Ludwig Enterprises Inc. (OTC:LUDG) Announces Patent Filing for Breakthrough in Identifying mRNA Genes Associated with Certain Cancers
March 06, 2024 08:00 ET
|
Ludwig Enterprises, Inc.
Ludwig Enterprises, Inc. (OTC: LUDG): A US-based biotechnology company is pleased to announce the successful filing of its provisional patent
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
February 28, 2024 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla. and BUNNIK, the Netherlands, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company...
Global Nucleic Acid Isolation and Purification Research 2023-2030: Growth Opportunities in Emerging Economies and Improving Regulatory and Reimbursement Scenario
January 03, 2024 06:23 ET
|
Research and Markets
Dublin, Jan. 03, 2024 (GLOBE NEWSWIRE) -- The "Nucleic Acid Isolation and Purification Market by Product (Kits, Reagents, Instruments), Method (Column, Magnetic Beads), Type (Genomic DNA, Plasmid...
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
November 29, 2023 08:30 ET
|
Dyadic International, Inc.
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
20Med Therapeutics Appoints Industry Veteran Hugo Fry as Chief Business Officer to Expedite mRNA Vaccine Delivery Platform Program
November 29, 2023 03:00 ET
|
20MED Therapeutics B.V.
Leiden, The Netherlands, November 29, 2023 – 20Med Therapeutics, a leader in non-viral delivery of mRNA vaccines, today announced the appointment of Hugo Fry as Chief Business Officer. His appointment...
Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa
November 20, 2023 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic to Present at Industry and Investor Events in October
September 29, 2023 08:30 ET
|
Dyadic International, Inc.
Dyadic to Present at Industry and Investor Events in October
Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
September 26, 2023 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla. and PARIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS ("bYoRNA") today announced that they entered into a development and...
COVID-19 Vaccine Market Predicted to Reach USD 9.9 billion by 2031, Garnering -13.6% CAGR: TMR Report
September 14, 2023 09:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The COVID-19 vaccine market was estimated to have acquired US$ 92.6 billion in 2021. It is...
RNA Therapy Clinical Trials Market Report 2023-2030: Strategies and Collaborations Shaping the Industry
August 29, 2023 04:48 ET
|
Research and Markets
Dublin, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The "RNA Therapy Clinical Trials Market Size, Share & Trends Analysis Report, 2023-2030" report has been added to ResearchAndMarkets.com's offering. ...